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Abstract
　Tuberculosis （TB） and human immunodeficiency virus （HIV） Co-Infection brings several 
therapeutic challenges. To treat co-infected patients, some key points must be considered, 
including the dosing period of anti-TB drugs, preceding anti-TB interventions, and any history 
of treatment complications. These complications include adverse drug reactions, interactions 
between anti-TB and anti-HIV drugs, and immune reconstitution inflammatory syndrome 
（IRIS）. The success or failure of antiretroviral therapy （ART） critically depends on addressing 
treatment complications. The administration period of anti-TB drugs takes into account the 
organism’s drug susceptibility. Administration of these drugs must be continued, even when 
anti-HIV drugs must be interrupted due to uncontrolled HIV infection. Combination regimens 
including both anti-TB and -HIV drugs should be administered with careful attention to any 
allergies to each drug alone, fluctuations in drug concentrations, and drug interactions （e.g., 
between rifamycin and anti-HIV drugs）. In untreated HIV patients, the decision of when to start 
ART depends on CD4 cell count （above or below 50 cells/µL）. Patients with low CD4 counts 
are prone to develop IRIS, which may result in worsening of their general condition. However, 
because ART confers a better prognosis, early ART （within 2 weeks） is recommended after 
initiating tuberculosis treatment, despite the risk of IRIS.





















































































































































































































































Major criteria Minor criteria Exclusion criteria
（A） Atyp i ca l  p re sen ta t i on  o f 
opportunist ic  infect ion or 
tumors in patient responding to 
ART
（1） Increase in CD4+ T-cell count 
after ART
（1） Failure of treatment to OIs 
because of  microbia l  drug 
resistance
（B） Decrease in plasma HIV RNA 
level > 1 log 10 copies/ml 
（2） Increase in immune response 
specific to relevant pathogen
（2） Poor adherence to treatment for 
OI/absorption problems
　 （3） Spontaneous reso lut ion o f 
d i s e a s e  w i t h  n o  s p e c i f i c 
antimicrobial therapy or tumor 
chemotherapy while continuing 
ART 
 （3） Presence o f  other OIs  or 











For IRIS diagnosis patients must meet 2 major criteria （A + B） or one major criterion （A or B） plus 2 minor 
criteria （1, 2, or 3）, without the presence of exclusion criteria, IRIS immune reconstitution inflammatory syndrome, 



































　　　（Tohoku JEM　2009 Aug; 218（4）: 285-92. 症例から）
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